These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32492723)

  • 1. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants.
    Bavalia R; Middeldorp S; Weisser G; Espinola-Klein C
    Thromb Haemost; 2020 Jun; 120(6):899-911. PubMed ID: 32492723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
    Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
    Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
    J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
    Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
    J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
    Mills K; Hill C; King M; Pauley JL; Cober MP; Fenn NE; Omecene NE; Smith T; Sierra CM
    Am J Health Syst Pharm; 2023 Mar; 80(7):412-422. PubMed ID: 36610740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.